Showing results (121-130 of 179) with videos related to
Sort By:
Pageof 18
Breast Cancer Research and Treatment|October 30, 2013
A clinical trial of lovastatin for modification of biomarkers associated with breast cancer riskShaveta Vinayak, Erich J Schwartz, Kristin Jensen, et al.European Journal of Human Genetics : EJHG|October 3, 2013
The MLH1 c.-27C>A and c.85G>T variants are linked to dominantly inherited MLH1 epimutation and are borne on a European ancestral haplotypeChau-To Kwok, Ingrid P Vogelaar, Wendy A van Zelst-Stams, et al.Journal of Neuro-Oncology|April 2, 2024
Repurposing mebendazole against triple-negative breast cancer CNS metastasisAdrian J Rodrigues, Sophia B Chernikova, Yuelong Wang, et al.The Journal of Molecular Diagnostics : JMD|May 10, 2016
Detection of Germline Mutation in Hereditary Breast and/or Ovarian Cancers by Next-Generation Sequencing on a Four-Gene PanelAva Kwong, Vivian Y Shin, Chun H Au, et al.Familial Cancer|March 16, 2011
A novel de novo BRCA1 mutation in a Chinese woman with early onset breast cancerAva Kwong, Enders K O Ng, Edmund Y H Tang, et al.Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 7, 2012
Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic featuresDaniel T Chang, Rish K Pai, Lisa A Rybicki, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2008
Performance of BRCA1/2 mutation prediction models in Asian AmericansAllison W Kurian, Gail D Gong, Nicolette M Chun, et al.Breast Cancer Research and Treatment|December 25, 2017
Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancerMelinda L Telli, Jessica Hellyer, William Audeh, et al.Genome Biology|October 16, 2014
Metastatic tumor evolution and organoid modeling implicate TGFBR2 as a cancer driver in diffuse gastric cancerLincoln D Nadauld, Sarah Garcia, Georges Natsoulis, et al.Journal of Oncology Practice|September 8, 2016
A Retrospective Analysis of Precision Medicine Outcomes in Patients With Advanced Cancer Reveals Improved Progression-Free Survival Without Increased Health Care CostsDerrick S Haslem, S Burke Van Norman, Gail Fulde, et al.Pageof 18